| Index | S&P 500, DJIA | P/E | 116.22 | EPS (ttm) | 1.25 | Insider Own | 0.09% | Shs Outstand | 2.47B | Perf Week | -0.47% |
| Market Cap | 358.41B | Forward P/E | 15.75 | EPS next Y | 9.22 | Insider Trans | -8.62% | Shs Float | 2.46B | Perf Month | -1.83% |
| Enterprise Value | 405.17B | PEG | 2.98 | EPS next Q | - | Inst Own | 76.71% | Short Float | 1.15% | Perf Quarter | 11.10% |
| Income | 3.17B | P/S | 5.40 | EPS this Y | -70.33% | Inst Trans | 0.00% | Short Ratio | 2.88 | Perf Half Y | 29.82% |
| Sales | 66.40B | P/B | 8.54 | EPS next Y | 247.98% | ROA | 2.44% | Short Interest | 28.27M | Perf YTD | 38.01% |
| Book/sh | 17.02 | P/C | 50.19 | EPS next 5Y | 38.97% | ROE | 6.60% | 52W High | 156.91 -7.42% | Perf Year | 65.81% |
| Cash/sh | 2.89 | P/FCF | 22.31 | EPS past 3/5Y | 8.43% 21.23% | ROIC | 5.62% | 52W Low | 82.01 77.14% | Perf 3Y | 42.44% |
| Dividend Est. | 3.40 (2.34%) | EV/EBITDA | 29.09 | Sales past 3/5Y | 3.08% 9.35% | Gross Margin | 75.38% | Volatility | 2.98% 2.62% | Perf 5Y | 85.46% |
| Dividend TTM | 3.40 (2.34%) | EV/Sales | 6.10 | EPS Y/Y TTM | -81.45% | Oper. Margin | 16.65% | ATR (14) | 4.32 | Perf 10Y | 143.74% |
| Dividend Ex-Date | Sep 15, 2026 | Quick Ratio | 1.10 | Sales Y/Y TTM | 3.48% | Profit Margin | 4.78% | RSI (14) | 49.47 | Recom | 2.34 |
| Dividend Gr. 3/5Y | 5.42% 6.75% | Current Ratio | 1.32 | EPS Q/Q | -106.10% | SMA20 | 0.05% | Beta | 0.14 | Target Price | 157.94 |
| Payout | 261.52% | Debt/Eq | 0.96 | Sales Q/Q | 5.11% | SMA50 | -0.94% | Rel Volume | 0.82 | Prev Close | 147.24 |
| Employees | 74,000 | LT Debt/Eq | 0.90 | Earnings | Oct 29 | SMA200 | 15.42% | Avg Volume | 10.17M | Price | 145.27 |
| IPO Date | Jan 13, 1978 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 51.94% 1.45% | Net Debt/EBITDA | 3.38 | Volume | 8,375,870 | Change | -1.34% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-22-26 | Reiterated | Wells Fargo | Overweight | $170 → $165 |
| Oct-19-26 | Reiterated | Goldman Sachs | Buy | $160 → $155 |
| Oct-12-26 | Reiterated | RBC Capital | Sector Perform | $150 → $145 |
| Oct-08-26 | Reiterated | Cantor Fitzgerald | Neutral | $116 → $145 |
| Sep-29-26 | Reiterated | Scotiabank | Sector Outperform | $155 → $180 |
| Sep-11-26 | Reiterated | Berenberg Bank | $90 → $137 | |
| Sep-10-26 | Reiterated | HSBC | Buy | $150 → $172 |
| Sep-09-26 | Reiterated | Leerink Partners | Outperform | $110 → $161 |
| Sep-08-26 | Reiterated | Guggenheim | Buy | $146 → $170 |
| Sep-04-26 | Reiterated | Wells Fargo | Overweight | $150 → $170 |
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 66,400 | 64,926 | 64,168 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 16,350 | 18,195 | 15,193 | — | — | — | — | — | — | |
| Gross Profit | 50,050 | 46,731 | 48,975 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 10,394 | 10,731 | 10,100 | — | — | — | — | — | — | |
| Research and Development | 28,350 | 12,514 | 17,938 | — | — | — | — | — | — | |
| Other Operating Expense | 250 | 0 | 716 | — | — | — | — | — | — | |
| Operating Income | 11,056 | 23,486 | 20,221 | — | — | — | — | — | — | |
| Interest Expense | 1,263 | 1,357 | 1,271 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -3,845 | -1,062 | 986 | — | — | — | — | — | — | |
| Net Income Before Taxes | 5,948 | 21,067 | 19,936 | — | — | — | — | — | — | |
| Income Taxes | 2,779 | 2,804 | 2,803 | — | — | — | — | — | — | |
| Consolidated Net Income | 3,173 | 18,254 | 17,117 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 3,169 | 18,263 | 17,133 | — | — | — | — | — | — | |
| Net Income | 3,173 | 18,254 | 17,117 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.26 | 7.30 | 6.76 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.26 | 7.30 | 6.76 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.25 | 7.28 | 6.74 | — | — | — | — | — | — | |
| EBITDA | 13,926 | 28,262 | 25,706 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 116.22 | 14.46 | 14.76 | — | — | — | — | — | — | |
| Price To Sales Ratio | 5.41 | 4.06 | 3.93 | — | — | — | — | — | — | |
| Gross Margin | 75.38 | 71.98 | 76.32 | — | — | — | — | — | — | |
| Operating Margin | 16.65 | 36.17 | 31.51 | — | — | — | — | — | — | |
| Net Margin | 4.78 | 28.12 | 26.68 | — | — | — | — | — | — | |
| Shares Outstanding | 2,472 | 2,502 | 2,532 | — | — | — | — | — | — | |
| Market Capitalization | 359,107 | 263,361 | 251,883 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Guindo Chirfi | EVP, Access, Policy & Comms | Aug 13 '26 | Sale | 135.00 | 10,000 | 1,350,000 | 36,613 | Aug 13 |
| Zachary Jennifer | EVP, General Counsel | Aug 12 '26 | Option Exercise | 109.78 | 54,927 | 6,029,637 | 125,824 | Aug 13 |
| Zachary Jennifer | EVP, General Counsel | Aug 12 '26 | Sale | 133.46 | 80,315 | 10,718,495 | 45,509 | Aug 13 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Aug 12 '26 | Sale | 131.63 | 11,699 | 1,539,992 | 110,167 | Aug 12 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Aug 11 '26 | Sale | 131.76 | 12,837 | 1,691,426 | 121,866 | Aug 12 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Aug 10 '26 | Sale | 130.43 | 20,784 | 2,710,951 | 134,703 | Aug 12 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Aug 06 '26 | Sale | 130.38 | 6,050 | 788,772 | 155,487 | Aug 10 |
| Guindo Chirfi | EVP, Access, Policy & Comms | Aug 06 '26 | Sale | 131.00 | 15,000 | 1,965,000 | 46,613 | Aug 07 |
| Williams David Michael | EVP,Chief Info&Digital Officer | Aug 05 '26 | Option Exercise | 74.49 | 52,847 | 3,936,377 | 66,421 | Aug 07 |
| Maraldo David R. | EVP & Pres. MMD | Aug 05 '26 | Option Exercise | 82.25 | 18,706 | 1,538,495 | 27,921 | Aug 07 |
| Maraldo David R. | EVP & Pres. MMD | Aug 05 '26 | Sale | 128.72 | 2,686 | 345,736 | 18,212 | Aug 07 |
| Williams David Michael | EVP,Chief Info&Digital Officer | Aug 05 '26 | Sale | 128.77 | 34,705 | 4,468,987 | 31,716 | Aug 07 |
| Maraldo David R. | EVP & Pres. MMD | May 02 '26 | Option Exercise | 112.16 | 552 | 61,912 | 18,371 | May 05 |
| Smart Dalton E. III | SVP Fin. - Global Controller | May 02 '26 | Option Exercise | 112.16 | 383 | 42,957 | 9,520 | May 05 |
| Smart Dalton E. III | SVP Fin. - Global Controller | Apr 30 '26 | Option Exercise | 110.95 | 464 | 51,481 | 9,296 | May 01 |